Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study - PubMed (original) (raw)

Clinical Trial

. 2009 Aug 18;101(4):621-7.

doi: 10.1038/sj.bjc.6605211.

H Wasan, P Johnson, E Jones, L Dixon, R Swindell, S Baka, A Maraveyas, P Corrie, S Falk, S Gollins, F Lofts, L Evans, T Meyer, A Anthoney, T Iveson, M Highley, R Osborne, J Bridgewater

Affiliations

Clinical Trial

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

J W Valle et al. Br J Cancer. 2009.

Abstract

Background: We assessed the activity of gemcitabine (G) and cisplatin/gemcitabine (C/G) in patients with locally advanced (LA) or metastatic (M) (advanced) biliary cancers (ABC) for whom there is no standard chemotherapy.

Methods: Patients, aged > or =18 years, with pathologically confirmed ABC, Karnofsky performance (KP) > or =60, and adequate haematological, hepatic and renal function were randomised to G 1000 mg m(-2) on D1, 8, 15 q28d (Arm A) or C 25 mg m(-2) followed by G 1000 mg m(-2) D1, 8 q21d (Arm B) for up to 6 months or disease progression.

Results: In total, 86 patients (A/B, n=44/42) were randomised between February 2002 and May 2004. Median age (64/62.5 years), KP, primary tumour site, earlier surgery, indwelling biliary stent and disease stage (LA: 25/38%) are comparable between treatment arms. Grade 3-4 toxicity included (A/B, % patients) anaemia (4.5/2.4), leukopenia (6.8/4.8), neutropenia (13.6/14.3), thrombocytopenia (9.1/11.9), lethargy (9.1/28.6), nausea/vomiting (0/7.1) and anorexia (2.3/4.8). Responses (WHO criteria, % of evaluable patients: A n=31 vs B n=36): no CRs; PR 22.6 vs 27.8%; SD 35.5 vs 47.1% for a tumour control rate (CR+PR+SD) of 58.0 vs 75.0%. The median TTP and 6-month progression-free survival (PFS) (the primary end point) were greater in the C/G arm (4.0 vs 8.0 months and 45.5 vs 57.1% in arms A and B, respectively).

Conclusion: Both regimens seem active in ABC. C/G is associated with an improved tumour control rate, TTP and 6-month PFS. The study has been extended (ABC-02 study) and powered to determine the effect on overall survival and the quality of life.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Trial schema.

Figure 2

Figure 2

Trial profile.

Figure 3

Figure 3

Kaplan–Meier curve of progression-free survival by treatment arm as a function of time.

References

    1. Agelaki S, Papakostas P, Stathopoulos G, Aravantinos G, Kalbakis K, Sarra E, Souglakos J, Kakolyris S, Kouroussis S, Androulakis N, Vardakis N, Georgoulias V (1999) Phase II study of docetaxel with G-CSF support as first-line treatment for unresectable or advanced biliary tract carcinoma: a multicentre phase II trial. Proc Am Soc Clin Oncol 18: 276a (abstract 1058)
    1. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ (1995) Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31a: 2335–2340 - PubMed
    1. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [see comments]. J Clin Oncol 15: 2403–2413 - PubMed
    1. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG (1994) Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29–34 - PubMed
    1. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim YH (2000) Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 23: 425–428 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources